16,186 reports of this reaction
3.9% of all ADAPALENE reports
#8 most reported adverse reaction
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION is the #8 most commonly reported adverse reaction for ADAPALENE, manufactured by Alchemee, LLC. There are 16,186 FDA adverse event reports linking ADAPALENE to INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION. This represents approximately 3.9% of all 416,192 adverse event reports for this drug.
Patients taking ADAPALENE who experience inappropriate schedule of product administration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION is moderately reported among ADAPALENE users, representing a notable but not dominant share of adverse events.
In addition to inappropriate schedule of product administration, the following adverse reactions have been reported for ADAPALENE:
The following drugs have also been linked to inappropriate schedule of product administration in FDA adverse event reports:
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION has been reported as an adverse event in 16,186 FDA reports for ADAPALENE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION accounts for approximately 3.9% of all adverse event reports for ADAPALENE, making it a notable side effect.
If you experience inappropriate schedule of product administration while taking ADAPALENE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.